An updated review of the existing knowledge regarding uremic toxins facilitates the design of experimental studies. We performed a literature search and found 621 articles about uremic toxicity published after a 2003 review of this topic. Eighty-seven records provided serum or blood measurements of one or more solutes in patients with CKD. These records described 32 previously known uremic toxins and 56 newly reported solutes. The articles most frequently reported concentrations of b2-microglobulin, indoxyl sulfate, homocysteine, uric acid, and parathyroid hormone. We found most solutes (59%) in only one report. Compared with previous results, more recent articles reported higher uremic concentrations of many solutes, including carboxymethyllysine, cystatin C, and parathyroid hormone. However, five solutes had uremic concentrations less than 10% of the originally reported values. Furthermore, the uremic concentrations of four solutes did not exceed their respective normal concentrations, although they had been previously described as uremic retention solutes. In summary, this review extends the classification of uremic retention solutes and their normal and uremic concentrations, and it should aid the design of experiments to study the biologic effects of these solutes in CKD. The uremic syndrome is characterized by the retention of various solutes that would normally be excreted by the kidneys. The substances that interact negatively with biologic functions are called uremic toxins. In the past years, research on uremic toxicity has been very dynamic and resulted in the identification of dozens of retention solutes, including several uremic toxins. In 2003, the European Uremic Toxin Work Group (http://www.uremic-toxins.org/) proposed a classification of 90 retention solutes providing data on normal and pathologic serum concentrations. 1 In 2007, results were further discussed and expanded with the addition of 14 solutes. 2, 3 This collaborative work focused on the highest mean or median concentration of the solutes measured in a uremic population and the highest individual uremic concentration. These data were particularly relevant for researchers on uremic toxicity, and they became a successful tool for allowing use of standardized and biologically relevant concentrations in experimental settings. More recently, scientific and technological progress resulted in the identification of many new uremic retention solutes, particularly thanks to nontargeted approaches such as metabolomic and proteomic profiling. 4, 5 To maintain experimental guidelines in keeping with current knowledge, it seemed necessary to propose an update of the encyclopedic review.
The uremic syndrome is characterized by the retention of various solutes that would normally be excreted by the kidneys. The substances that interact negatively with biologic functions are called uremic toxins. In the past years, research on uremic toxicity has been very dynamic and resulted in the identification of dozens of retention solutes, including several uremic toxins. In 2003, the European Uremic Toxin Work Group (http://www.uremic-toxins.org/) proposed a classification of 90 retention solutes providing data on normal and pathologic serum concentrations. 1 In 2007, results were further discussed and expanded with the addition of 14 solutes. 2, 3 This collaborative work focused on the highest mean or median concentration of the solutes measured in a uremic population and the highest individual uremic concentration. These data were particularly relevant for researchers on uremic toxicity, and they became a successful tool for allowing use of standardized and biologically relevant concentrations in experimental settings. More recently, scientific and technological progress resulted in the identification of many new uremic retention solutes, particularly thanks to nontargeted approaches such as metabolomic and proteomic profiling. 4, 5 To maintain experimental guidelines in keeping with current knowledge, it seemed necessary to propose an update of the encyclopedic review. 1 It was decided to study the publications from after the first review and compare results with previous findings. With this comparison, it became possible to identify new uremic retention solutes and provide an external validation of the original tool. We reviewed all original articles on uremic toxicity published between 2003 and April 2011 and extracted all serum concentrations of uremic retention solutes measured in uremic populations and healthy controls.
RESULTS

Overview of Uremic Toxin Research
Between 2003 and April 2011, 621 articles dealing with uremic toxins in renal patients matched a corresponding PubMed electronic search (www.pubmed.com). Eighty-seven articles (14%) provided data on uremic retention solute concentrations in CKD patients and were also included in the analysis (Supplemental Material 1). Most studies were performed in patients undergoing dialysis (chronic hemodialysis, 80 .5% of studies; peritoneal dialysis, 2% of studies), and 14% of studies were performed in nondialyzed CKD patients. The remaining 3.5% of studies included both dialyzed and nondialyzed CKD patients. According to the classification of uremic retention solutes based on size and binding properties, 2 free watersoluble low molecular mass compounds (,0.5 kD) represented 46% of the 88 solutes; 28% of solutes were middle molecules (0.5-60 kD), and 24% of solutes were protein-bound solutes ( Table 1) . Most of the 88 solutes (59%) had only been quantified within one study; these solutes were mainly free water-soluble compounds (64%), whereas 23% of solutes were middle molecules, and the remaining 13% of solutes were protein-bound solutes. Among the 36 solutes for which several concentrations could be included, 45% were protein-bound solutes, 36% were middle molecules, and 19% were small water-soluble compounds. Uremic concentrations are presented in Tables 2-4 . Molar concentrations ranged from a few picomoles per liter for ILs to micromoles per liter for phenylacetic acid. 22, 31 The highest mass concentration was detected for the acute phase macromolecule a1-acid glycoprotein. 54 Most frequently reported concentrations concerned b2-microglobulin, indoxyl sulfate, homocysteine, uric acid, and parathyroid hormone (PTH). There were large variations in binding of protein-bound solutes. The free fraction of acrolein represented less than 1% (range=0.72-0.84) of total acrolein. On average, the free fraction of p-cresylsulfate was 9.0% (4.2-13.8), the free fraction of indoxyl sulfate was 9.4% (4.5-12.9), and the free fraction of indole-3-acetic acid was 16.3% (14.3-18. 3). The free fraction was greater for hippuric acid (60%; range=49-71). Our approach failed to include 58 uremic retention solutes that had been listed along with their uremic and normal concentrations in the previous classification. 1 Several isolation and detection techniques were applied to quantify toxins, including chromatography (ion exchange chromotography [IEC], gas chromatography [GC] , and HPLC), spectrophotometry, fluorometry, chemilumisnescence, nephelometry, radioimmunometry, nuclear magnetic resonance, and mass spectrometry (MS). However, uremic and normal concentrations were generally, but not always, measured with similar techniques (85% of solutes) (Tables 2-4) .
Comparison with Normal Concentrations
To evaluate the relative solute retention in uremia, we calculated the ratio of the mean of all reported uremic concentrations (M) to the normal concentration (N) measured in healthy controls (M/N). The ratio M/N ranged from 333 for phenylacetic acid to 0.3 for spermine (Tables 5-7 ). There were 21 solutes for which uremic concentrations were more than 10 times higher than normal (Table 5 ). There was a limited degree of retention in the case of 18 solutes for which the ratio M/N ranged between one and two (Table 6 ). For four compounds from the original uremic retention list, the ratio M/N was below one, which suggests that they might not be retention solutes (spermine, spermidine, guanidinoacetic acid, and malondialdehyde) ( Table 7) .
Comparison with Previously Reported Concentrations
Of the 88 retention solutes, 56 solutes had not been presented in the list of uremic toxins published in 2003 and 2007 (Table 1) . 1, 2 Because their uremic concentrations exceeded those concentrations of healthy controls, they were subsequently added to the list. However, there were 32 solutes that had already been included in the list of known uremic retention solutes. These solutes are presented in Figure 1 along with the ratio of the highest uremic concentrations found in the present analysis (H) to the concentrations found in the original review (h). This index ranged from 0.04 for TNF-a to 4.30 for carboxymethyllysine. Interestingly, the ratio H/h exceeded one for nine solutes, signifying that recent publications provided a more elevated highest concentration and justifying the need for updating the list of uremic concentrations. There were 12 solutes for which the highest concentration was less than one-half of the original highest report (ratio H/h below 0.5). For five of the solutes, it was even below 10% of the original report (H/h,0.1). For these compounds, we evaluated the representativeness of highest concentrations by graphical analyses. Data from both the present work and the previous review 1 were pooled, and possible outliers were sought using box plots.
Results concerning solutes with four concentrations or more are displayed in Figure 2 . There were, indeed, outlying maximal values for all four solutes that had all been published before 2003. After exclusion of suspected outliers, the corrected H/h ratios substantially increased, reaching scores above 10% (H/h: IL-6, 0.73; TNF-a, 0.47; methylguanidine, 0.16; guanidino succinic acid, 0.14)
.
Variability in Concentrations
To analyze variability in reported concentrations, the ratio H/L of the H to the lowest concentrations (L) found in uremic populations was used as an index of the range of the observed uremic concentrations. Substantial variability, as previously defined by a ratio exceeding 8. The review of the literature resulted in the inclusion of 88 published articles, with data on 32 known uremic toxins and 56 newly identified retention solutes, which were consequently added to the list of uremic toxins. A time limit was necessary to perform this analysis, but in such a dynamic field, new toxins are continuously identified. Recently, the strong vasoconstrictor uridine adenosine tetraphosphate (Up 4 A) was described as a uremic toxin. CKD patients had, on average, a 5.2-fold higher Up 4 A plasma concentration compared with healthy subjects, and this increased Up 4 A concentration may influence blood pressure, proliferation rate of vascular smooth muscle cells, and calcification processes in CKD patients. 93, 94 A molecular mass threshold was also applied, and molecules above 60 kD were excluded from the analysis, because these solutes cannot be filtered by the glomeruli. However, although their concentrations are not directly associated with glomerular function, several large acute phase proteins (a2-macroglobulin, fibrinogen, 45, 70 were increased in CKD, and they could have a significant diagnostic and pathophysiologic value. 98, 99 However, reviewing all solutes that were evaluated in a sample of publications on uremic patients, we identified molecules that were reduced in uremia (bilirubin, reduced glutathione, a1-antitrypsine, arginine, and homoarginine). 10, 35, 81, 100 Because these solutes are associated with antioxidant, anti-inflammatory, and vasodilating properties, their reduced concentration could be involved in additional adverse effects of uremia. Performing this analysis, we faced several limitations related to data reporting. For instance, it is still frequent for -omics studies to report only strengths of associations without reporting concentrations. 4, 64 We were also limited by the use relative units, particularly concerning enzymes and advanced glycation end products (AGEs). 24, 39, 101, 102 Furthermore, we chose not to include results on k-light chains, because the concentration found in uremic patients was less than 1% of the values previously found in healthy or CKD populations (30-80 mg/L). 60, 103 Finally, because it was shown in 2005 that the reported serum p-cresol concentrations were actually caused by an artifact linked to deproteinization of p-cresylsulfate and p-cresylglucuronide, 104, 105 results on p-cresol were also excluded. Still, we found eight reports on p-cresol published after 2005. Warnings concerning the study of p-cresol have recently been discussed elsewhere. 106 Our research identified 32 solutes that had been included in the previous report in 2003 and observed considerable differences, with a general tendency to lower concentrations. Several reasons could explain these discrepancies. A general improvement in dialysis techniques could result in a more efficient toxin removal with, eventually, better blood profiles of dialyzed patients. This finding was shown with hemodiafiltration over hemodialysis for middle molecules and small watersoluble molecules such as urea. 27, 32, 56, 107 Methodological choices, in terms of quantification techniques, could also influence reported concentrations. A cross-sectional comparison of HPLC, MS, and ELISA determinations of ADMA showed large variability across and within techniques, and it found that MS was the most reliable measurement method. 108 A similar technical issue could explain the lower concentrations in guanidino compounds found in our analysis. Indeed, recent results were measured using IEC, whereas the previously reported values had been quantified by HPLC.
There were four compounds that did not clearly show uremic retention, although they had been presented as uremic solutes in previous classifications. 1,2 Results on guanidinoacetic acid confirmed that it is not a uremic toxin, because concentrations consistently decreased with CKD severity. 13, 18, 19, 64 Concerning spermine and spermidine, normal concentrations were not presented in the original review. 1 Results from age-matched normal and uremic patients showed that both concentrations and particularly, spermine were reduced in uremia. 53 Furthermore, there was a clear increase in both acrolein, a toxic spermine oxidation product, and in the activity of the responsible oxidase. 53 Interestingly, concentrations in malondialdehyde actually increased with CKD severity, which supports its classification as a uremic retention solute. 22, 84 Whether normal and uremic concentrations of retention solutes were comparable is a difficult aspect of this study, especially when results are drawn from different sources. When available, we used internal controls to estimate normal concentrations. Furthermore, to minimize the impact of the methodological choices, efforts were made to select studies using the same techniques. When reference ranges were given by age strata, we used age-matched populations. Comfortingly, sensitivity analyses suggested that the choice of normal concentrations did not substantially modify results.
We believe that this analysis provided relevant information on uremic retention solutes, which should be taken into account when testing uremic retention solute toxicity. With the addition of 56 uremic retention solutes, this extended classification of uremic retention solutes proved that it was timely and useful. It should be used jointly with the previous publications 1,2 as a complementary tool, giving additional insight into concentration values and variability of retention solutes found in uremic populations.
CONCISE METHODS
Search and Selection Criteria
The PubMed database was searched for articles published from January 1, 2003 to April 1, 2011 dealing with uremic toxins in renal patients using the following keywords: (uremi* OR uraemi*) AND (toxin* OR toxic*) AND patients AND (renal failure chronic OR kidney disease OR CKD). The aim was to retrieve uremic and normal serum or plasma concentrations of uremic retention solutes and exclude common solutes such as creatinine and urea, inorganic compounds, and large molecules over 60 kD that are not filtered by the glomerulus. To be included in our study, plasma concentrations had to be measured in adult patients with CKD stages 3-5. All solutes that had been listed in the previous encyclopedic reviews were included. For other solutes, only those solutes in which uremic concentrations exceeded normal concentrations were included. For populations receiving renal replacement therapy by peritoneal or hemodialysis, only pretreatment concentrations were included. To avoid the effect of metabolic differences, reactive carbonyl compounds (RCCs), AGEs, and advanced lipoperoxidation end products were measured in nondiabetic patients. When necessary, blood concentrations were estimated using a blood protein concentration of 70 g/L and serum albumin concentration of 35 g/L. 1, 109 All concentrations are presented in grams per liter. Data that were originally reported in moles per liter were transformed into mass concentrations by multiplying with the molecular weight. Suspected unit errors were recorded and studied separately. All original concentrations were given as mean (SD) or median (range). For each solute, we calculated M and identified H and L reported concentrations. In contrast with our previous study, the maximal individual concentrations were not recorded or estimated. However, under the hypothesis of a normal distribution, it can be approximated using the formula C individual max =M+2SD. 1 For each solute, we reported N measured in healthy controls. N values were preferably extracted from the same publication reporting the highest concentration H or if not possible, another included study. Otherwise, normal concentration was taken from the 2003 encyclopedic review or external sources. N levels were preferably recorded as means (SD). If reported as a range or confidence interval, the upper bound or maximal value was extracted and presented using a less than symbol. Finally, for solutes of which data were presented in the original review, the 2003 h value was also extracted.
Calculations and Analyses
The relative solute retention in uremia was studied using M/N. Solutes scoring more than 10 were arbitrarily defined as largely increased, whereas scorings below 2 were interpreted as showing limited evidence of uremic retention. For solutes that had been included in the 2003 review, highest reported values were compared using the H/h ratio. Between-study variability was assessed using H/L, which is an index of the width of the concentration range. Low evidence of variability has been previously defined as a ratio below 3, whereas a ratio exceeding 8.5 is evidence of substantial variability. 5 Additionally, the coefficient of variability was calculated for results based on four data or more using the formula coefficient of variability= SD/M. Finally, graphical analyses of data dispersion using box plots were undertaken for solutes that had four values or more. Values outside Tukey's inner fence were considered to be suspected outliers. 2, 110 Tukey's inner fence is defined as the range between 1.5 times the interquartile range below the first quartile to 1.5 times the interquartile range above the third quartile. Sensitivity analyses were performed to evaluate the influence of methodological choices. The effect of CKD stage (predialytic versus dialytic stages) on concentrations was assessed by exact Wilcoxon tests for two independent samples. The difference between N and other available control concentrations was assessed by a paired t test. The correlation between M/N ratios using N or other control concentrations was evaluated using Pearson's product moment correlation coefficient. Statistical tests were performed with a 5% type I error. Calculations and analyses were performed with Excel 2007 (Microsoft Corp., Redmond, WA) and SAS version 9.2 (SAS Institute, Cary, NC).
